Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EOLS NASDAQ:MNKD NASDAQ:SYRS NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$6.36-0.5%$4.80$3.86▼$10.62$420.81M1.28985,577 shs844,493 shsMNKDMannKind$3.52-0.8%$2.73$2.23▼$6.51$1.10B1.045.83 million shs9.53 million shsSYRSSyros Pharmaceuticals$0.00-50.0%$0.00$0.00▼$0.05$5K1.3119,114 shs1,893 shsWVEWAVE Life Sciences$7.18-0.8%$9.65$5.02▼$21.73$1.39B-1.324.08 million shs2.55 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus0.00%+18.55%+56.23%+42.00%-45.86%MNKDMannKind0.00%+25.44%+36.02%-38.58%-26.80%SYRSSyros Pharmaceuticals0.00%0.00%-50.00%-75.00%-99.49%WVEWAVE Life Sciences0.00%+2.55%+1.97%-46.17%+11.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$6.36-0.5%$4.80$3.86▼$10.62$420.81M1.28985,577 shs844,493 shsMNKDMannKind$3.52-0.8%$2.73$2.23▼$6.51$1.10B1.045.83 million shs9.53 million shsSYRSSyros Pharmaceuticals$0.00-50.0%$0.00$0.00▼$0.05$5K1.3119,114 shs1,893 shsWVEWAVE Life Sciences$7.18-0.8%$9.65$5.02▼$21.73$1.39B-1.324.08 million shs2.55 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus0.00%+18.55%+56.23%+42.00%-45.86%MNKDMannKind0.00%+25.44%+36.02%-38.58%-26.80%SYRSSyros Pharmaceuticals0.00%0.00%-50.00%-75.00%-99.49%WVEWAVE Life Sciences0.00%+2.55%+1.97%-46.17%+11.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOLSEvolus 2.50Moderate Buy$16.00151.57% UpsideMNKDMannKind 2.60Moderate Buy$8.84151.24% UpsideSYRSSyros Pharmaceuticals 0.00N/AN/AN/AWVEWAVE Life Sciences 2.87Moderate Buy$27.50283.01% UpsideCurrent Analyst Ratings BreakdownLatest WVE, SYRS, MNKD, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $10.005/7/2026MNKDMannKind HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.005/7/2026MNKDMannKind Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$3.50 ➝ $4.755/7/2026MNKDMannKind MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.005/4/2026WVEWAVE Life Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $24.004/30/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.004/29/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00 ➝ $15.004/28/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $8.004/24/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026WVEWAVE Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026MNKDMannKind Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOLSEvolus$297.18M1.41N/AN/A($0.44) per share-14.45MNKDMannKind$348.97M3.12$0.06 per share57.37($0.19) per share-18.53SYRSSyros Pharmaceuticals$386K0.01N/AN/A$0.79 per share0.00WVEWAVE Life Sciences$42.73M32.33N/AN/A$2.66 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOLSEvolus-$51.64M-$0.67N/A127.20N/A-14.39%N/A-19.03%N/AMNKDMannKind$5.86M-$0.07N/A70.40N/A-6.63%-11.21%-3.92%N/ASYRSSyros Pharmaceuticals-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%5/12/2026 (Estimated)WVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%N/ALatest WVE, SYRS, MNKD, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026MNKDMannKind-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 million5/4/2026Q1 2026EOLSEvolus-$0.14-$0.16-$0.02-$0.16$72.52 million$73.14 million4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 million3/3/2026Q4 2025EOLSEvolus$0.09$0.0020-$0.0880N/A$89.58 million$90.30 million2/26/2026Q4 2025MNKDMannKind-$0.01-$0.05-$0.04-$0.05$99.85 million$111.96 million2/26/2026Q4 2025WVEWAVE Life Sciences-$0.28-$0.30-$0.02-$0.30$15.68 million$17.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEOLSEvolusN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOLSEvolusN/A2.041.54MNKDMannKindN/A1.871.50SYRSSyros PharmaceuticalsN/A2.252.25WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOLSEvolus90.69%MNKDMannKind49.55%SYRSSyros Pharmaceuticals91.47%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipEOLSEvolus5.90%MNKDMannKind2.60%SYRSSyros Pharmaceuticals12.26%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOLSEvolus17065.86 million61.97 millionOptionableMNKDMannKind400308.95 million300.77 millionOptionableSYRSSyros Pharmaceuticals12026.83 million23.54 millionNo DataWVEWAVE Life Sciences240192.38 million146.25 millionOptionableWVE, SYRS, MNKD, and EOLS HeadlinesRecent News About These CompaniesGrowth Investors: Industry Analysts Just Upgraded Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts By 91%May 8 at 5:29 PM | finance.yahoo.comWave Life Sciences: Good Platform, Mixed Clinical Trial Data, HoldMay 7 at 11:02 AM | seekingalpha.comHC Wainwright Has Bullish Forecast for WVE Q2 EarningsMay 4, 2026 | americanbankingnews.comHC Wainwright Expects Higher Earnings for WAVE Life SciencesMay 4, 2026 | marketbeat.comCanaccord Genuity Reaffirms Their Buy Rating on Wave Life Sciences (WVE)May 3, 2026 | theglobeandmail.comA Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price DeclineMay 3, 2026 | finance.yahoo.comPictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVEMay 2, 2026 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for WAVE Life Sciences (NASDAQ:WVE) Stock PriceMay 2, 2026 | americanbankingnews.comWAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street ZenMay 2, 2026 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 2, 2026 | americanbankingnews.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by AnalystsMay 2, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Given New $43.00 Price Target at Canaccord Genuity GroupApril 30, 2026 | marketbeat.comWAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...April 29, 2026 | finance.yahoo.comWAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6% - Here's What HappenedApril 29, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPSApril 29, 2026 | marketbeat.comWAVE Life Sciences Q1 Earnings Call HighlightsApril 28, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading 5.5% Higher - Time to Buy?April 28, 2026 | marketbeat.comWave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue EstimatesApril 28, 2026 | zacks.comWave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 28, 2026 | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Should You Sell?April 24, 2026 | marketbeat.comWAVE Life Sciences (WVE) Projected to Post Earnings on TuesdayApril 24, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWVE, SYRS, MNKD, and EOLS Company DescriptionsEvolus NASDAQ:EOLS$6.36 -0.03 (-0.47%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$6.31 -0.05 (-0.79%) As of 05/8/2026 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.MannKind NASDAQ:MNKD$3.52 -0.03 (-0.85%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.59 +0.07 (+1.99%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Syros Pharmaceuticals NASDAQ:SYRS$0.0002 0.00 (-50.00%) As of 05/8/2026 03:31 PM EasternSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.WAVE Life Sciences NASDAQ:WVE$7.18 -0.06 (-0.83%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$7.24 +0.07 (+0.91%) As of 05/8/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
